Phibro Animal Health to report Q4 FY26 results on August 26

0 min read | Published on 20 Aug 2026, 02:07 AM |Updated on 20 Aug 2026, 02:07 AM

Reviewed by

Ashish TScanX News Team

Key Highlights

Phibro Animal Health Corporation will release Q4 and FY26 results on August 26, 2026. A management conference call follows on August 27 at 9:00 am ET. Investors can join via webcast or phone using conference ID 3927884.

*this image is generated using AI for illustrative purposes only.

Phibro Animal Health Corporation (NASDAQ: PAHC) will announce its fourth quarter and fiscal year 2026 financial results after market close on Wednesday, August 26, 2026. The global animal health and mineral nutrition company will provide an update on its operational and financial performance for the period.

Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 am Eastern Time to discuss the results. Interested parties can access the live event via the company's investor relations website or by dialing the provided telephone numbers.

Conference Call Details

Participants can listen to the discussion and view presentation slides through the following channels:

Webcast: Available at investors.pahc.com
U.S. and Canada Dial-in: +1 (888) 330-2022
International Dial-in: +1 (365) 977-0051
Conference ID: 3927884

A replay of the webcast will be available approximately two hours after the conclusion of the live event on the investor relations site.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. The firm partners with livestock producers, farmers, veterinarians, and consumers to provide solutions that maintain and enhance animal health for both farm and companion animals.

How will Phibro's Q4 2026 results reflect the impact of recent regulatory changes in animal health across key global markets?

What strategic acquisitions or partnerships might Phibro pursue to diversify its revenue streams beyond traditional mineral nutrition?

How are shifting consumer preferences for sustainable livestock practices influencing Phibro's product development and R&D priorities?

Phibro Animal Health declares $0.12 quarterly dividend

1 min read | Published on 29 Jul 2026, 04:51 AM |Updated on 29 Jul 2026, 04:51 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Phibro Animal Health Corporation has declared a quarterly cash dividend of $0.12 per share for its Class A and Class B common stockholders. The record date is set for September 02, 2026, with payments to be made on September 23, 2026.

*this image is generated using AI for illustrative purposes only.

Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock today. The Board of Directors approved the distribution, which is payable on September 23, 2026, to stockholders of record at the close of business on September 2, 2026.

The declaration reflects the company’s ongoing commitment to returning capital to shareholders while maintaining financial flexibility. Phibro Animal Health operates as a leading global diversified animal health and nutrition company, serving livestock producers, farmers, veterinarians, and consumers.

Dividend Details

The key dates and terms for the upcoming dividend payment are outlined below:

Detail	Information
Dividend Amount	$0.12 per share
Record Date	September 02, 2026
Payment Date	September 23, 2026
Applicable Shares	Class A and Class B Common Stock

Investors must hold shares by the close of business on the record date to be eligible for the payment. The dividend applies equally to both classes of common stock listed on the NASDAQ under the ticker symbol PAHC.

About the Company

Phibro Animal Health Corporation provides solutions to help maintain and enhance the health of farm and companion animals. The company positions itself as a trusted partner for its diverse customer base, offering products that support animal health and nutrition globally. For further information, investors can visit www.pahc.com .

How does the $0.12 per share dividend align with Phibro's current free cash flow generation and payout ratio targets?

What impact might this capital return strategy have on Phibro's ability to fund future R&D initiatives or potential M&A activities in the animal health sector?

Given the global nature of Phibro's operations, how could fluctuating raw material costs or supply chain disruptions affect the sustainability of this dividend in subsequent quarters?